LPCN — Lipocine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1535955 ·
Last close
$2.10
Market Cap
$17.31M
52W High
$12.37
52W Low
$1.81
ADV30
33,770
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 190,099 | -1,851,290 | -2,842,246 | -2,622,595 | 23,835,361 | 4,979,430 | 2,067,957 |
| Mar 2026 | 119,397 | — | -3,849,464 | -3,671,894 | 25,358,166 | 5,015,608 | 2,527,843 |
| Dec 2025 | 1,145,390 | — | -2,515,801 | -2,370,084 | 17,005,612 | 5,205,842 | 2,528,196 |
| Sep 2025 | 114,574 | — | -3,361,040 | -3,186,832 | 16,073,167 | 3,901,040 | 1,931,119 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,190,794
Investing CF
$-6,146,470
Financing CF
$16,272,714
CapEx
$-10,019
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,690,856
Inventory
—
Receivables
$291,164
ST Investments
$18,287,179
EBIT TTM
$-12,568,551
Pretax Income TTM
$-11,851,205
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,569,460
EBITDA
$-12,509,986
Free Cash Flow
$-6,939,857
Enterprise Value
$-4,294,347
Total Cash
$23,266,608
Total Debt
$257,807
Shares Out
8,244,253
Trailing EPS
$-1.85
Book Value
$2.64
ROE
-60.9%
ROA
-37.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,976,677 | -10,371,379 | -9,627,505 | 17,005,612 | 2,528,196 | 14,477,416 | -9,760,721 |
| Dec 2024 | 11,198,144 | -1,155,035 | 8,352 | 22,510,501 | 1,512,936 | 20,997,565 | -1,221,233 |
| Dec 2023 | -2,850,818 | -17,930,957 | -16,352,082 | 23,001,072 | 2,631,629 | 20,369,443 | -11,865,991 |
| Dec 2022 | 500,000 | -12,119,375 | -10,758,636 | 37,542,922 | 1,907,982 | 35,634,940 | -11,968,819 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INTI | Inhibitor Therapeutics, Inc. | $17.48M | $0.10 | — |
| BFRI | Biofrontera Inc. | $17.53M | $1.18 | — |
| NCEL | NewcelX Ltd. | $17.02M | $2.95 | — |
| CLRB | Cellectar Biosciences, Inc. | $17.01M | $1.80 | — |
| TVRD | Tvardi Therapeutics, Inc. | $16.94M | $1.27 | — |
News headlines (Yahoo Finance, 1h cache)
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
2026-09-23 16:00 · Yahoo
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
2026-06-04 12:00 · Yahoo
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
2026-05-19 12:00 · Yahoo
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
2026-05-18 12:00 · Yahoo
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
2026-05-07 20:05 · Yahoo
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 19:15 · Yahoo
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
2026-09-14 12:00 · Yahoo
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
2026-08-04 12:00 · Yahoo
Lipocine Appoints Michael J. Grissinger to Board of Directors
2026-08-03 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.